HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G CEO Pledges Driving Top-Line Growth With Consumer-Centric Focus

This article was originally published in The Tan Sheet

Executive Summary

New P&G CEO David Taylor counts on top-line growth through a consumer-centric focus, with “several hundred million” more dollars in advertising later in 2016, and another $10bn in cost-cutting over the next five years as key pieces of the firm's turn-around.

You may also be interested in...



If P&G Seeks OTC Sale, Pharma Buyers Might Line Up

P&G's activist investor Trian Fund Management is known for pressuring big companies to break up. The OTC business would likely have plenty of potential buyers.

P&G Could Lean Toward OTC Brand Sales With Activist Investor Influence

Analysts consider the potential for P&G splitting up or selling OTC or beauty care assets following CEO David Taylor's recent comments on possible moves with activist investor Trian. Analysts weigh in on the potential for sale or swap of brands and whether the moves would help.

P&G Could Lean Toward OTC Brand Sales With Activist Investor Influence

Analysts consider the potential for P&G splitting up or selling OTC or beauty care assets following CEO David Taylor's recent comments on possible moves with activist investor Trian. Analysts weigh in on the potential for sale or swap of brands and whether the moves would help.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel